Advancing knowledge, awareness, and education of gene and cell therapy
ASGCT Policy Summit
November 4 – 6 | Washington D.C.

What is ASGCT?

The American Society of Gene & Cell Therapy (ASGCT) is the primary membership organization for scientists, physicians, professionals, and patient advocates involved in gene and cell therapy. Our mission is to advance knowledge, awareness, and education leading to discovery and clinical application of gene and cell therapies to alleviate disease—we do that by serving as a catalyst to transform medicine by advancing gene and cell therapies to benefit patients and society.

22nd Annual Meeting

April 29 - May 2, 2019 - Washington, D.C.


Annual Meeting Recap

Edith Pfister, Ph.D., associate editor of ASGCT's newsletter The Vector, not only attended the record-breaking ASGCT 22nd Annual Meeting but presented an abstract on the meeting's final day. Read about her experience and recap an incredible week of science.

Certificate of Attendance

Generate a Certificate

Attendees of the ASGCT 22nd Annual Meeting are able to generate a certificate of attendance using our online system.

Learn More

Full Abstract Book

All of the abstracts presented at the 22nd Annual Meeting are available in one collection.

Read Abstracts
ASGCT Membership
ASGCT membership is essential to scientists working in gene and cell therapy

Membership Benefits:

  • Education & Training
  • Advocacy Opportunities
  • Career Growth
  • Reduced Annual Meeting Fees
  • Free Molecular Therapy Subscription

Become a Member

Molecular Therapy:

The International Journal of Molecular and Cellular Therapeutics

Official Journal of the American Society of Gene & Cell Therapy

Molecular Therapy is the leading journal for gene and cell therapy research, publishing important peer-reviewed research and cutting-edge reviews and commentaries.

Read Current Issue

The Latest in Gene & Cell Therapy

ASGCT is your unbiased source for reliable, scientific information, news, and breakthroughs in gene and cell therapy.

Featured News

May 24, 2019

FDA Approves Zolgensma

Zolgensma (Novartis, AveXis), an AAV-delivered gene therapy used to treat spinal muscular atrophy (SMA) type 1 also known as AVXS-101, was approved for clinical use in the United States by the Food and Drug Administration today.

Read More

See All News

Educational Resources

Gene Therapy Basics

Gene therapy has been studied for more than 40 years and can help stop or slow the effects of disease on the most basic level of the human body—our genes. And to understand how it works, we’ll start at the basics.

Learn More

Different Approaches

Gene therapy, cell therapy and gene editing are fields of biomedical research with a similar goal in mind: To treat disease by changing our genetic makeup. What do they have in common, and what makes them different?

Learn More

Developing a Treatment

Gene therapies take years to go from theoretical concepts, to preclinical trials, to clinical trials, and, finally, into actual treatments that can improve the lives of patients. Here we learn about the process of developing a treatment.

Learn More

See All Articles